Terms: = Ovarian cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Prognosis
28 results:
1. Methylation of brd4 by PRMT1 regulates brd4 phosphorylation and promotes ovarian cancer invasion.
Liu Y; Liu H; Ye M; Jiang M; Chen X; Song G; Ji H; Wang ZW; Zhu X
Cell Death Dis; 2023 Sep; 14(9):624. PubMed ID: 37737256
[TBL] [Abstract] [Full Text] [Related]
2. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract] [Full Text] [Related]
3. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
4. Gynecological cancer prognosis using machine learning techniques: A systematic review of the last three decades (1990-2022).
Sheehy J; Rutledge H; Acharya UR; Loh HW; Gururajan R; Tao X; Zhou X; Li Y; Gurney T; Kondalsamy-Chennakesavan S
Artif Intell Med; 2023 May; 139():102536. PubMed ID: 37100507
[TBL] [Abstract] [Full Text] [Related]
5. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract] [Full Text] [Related]
6. The role of distinct brd4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract] [Full Text] [Related]
7. p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
Mak VC; Li X; Rao L; Zhou Y; Tsao SW; Cheung LW
Neoplasia; 2021 Jul; 23(7):718-730. PubMed ID: 34144267
[TBL] [Abstract] [Full Text] [Related]
8. miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review.
Guo CM; Liu SQ; Sun MZ
Neoplasma; 2020 Mar; 67(2):215-228. PubMed ID: 31884798
[TBL] [Abstract] [Full Text] [Related]
9. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract] [Full Text] [Related]
10. Cold Atmospheric Plasma (cap) and cap-Stimulated Cell Culture Media Suppress ovarian cancer Cell Growth - A Putative Treatment Option in ovarian cancer Therapy.
Koensgen D; Besic I; Gümbel D; Kaul A; Weiss M; Diesing K; Kramer A; Bekeschus S; Mustea A; Stope MB
Anticancer Res; 2017 Dec; 37(12):6739-6744. PubMed ID: 29187451
[TBL] [Abstract] [Full Text] [Related]
11. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
Ma SK; Zhang HT; Wu LY; Liu LY
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
[TBL] [Abstract] [Full Text] [Related]
12. [Selecting postoperative chemotherapy regimen and optimizing therapy cycle for stage II-IV ovarian epithelial carcinoma].
Huang YW; Li YJ; Li MD
Ai Zheng; 2005 Aug; 24(8):994-7. PubMed ID: 16086880
[TBL] [Abstract] [Full Text] [Related]
13. [Primary peritoneal malignant tumor: clinical analysis of 28 cases].
Wu Y; Li WF
Ai Zheng; 2003 Nov; 22(11):1228-31. PubMed ID: 14613659
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract] [Full Text] [Related]
15. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years.
Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K
Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157
[TBL] [Abstract] [Full Text] [Related]
16. Chemotherapy in recurrent epithelial ovarian cancer (EOC): an analysis of prognostic factors.
Shamsunder S; Kumar L; Gupta S; Kumar S; Bhatla N; Singh R; Kochupillai V
J Obstet Gynaecol Res; 2000 Jun; 26(3):215-22. PubMed ID: 10932985
[TBL] [Abstract] [Full Text] [Related]
17. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
Wang PH; Yuan CC; Shyong WY; Chiang SC; Chao JY; Yen MS; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):220-5. PubMed ID: 10746418
[TBL] [Abstract] [Full Text] [Related]
18. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.
Kita T; Kikuchi Y; Kudoh K; Takano M; Goto T; Hirata J; Tode T; Nagata I
Oncol Rep; 2000; 7(2):327-31. PubMed ID: 10671681
[TBL] [Abstract] [Full Text] [Related]
19. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract] [Full Text] [Related]
20. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
Li M; Huang X
Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
[TBL] [Abstract] [Full Text] [Related]
[Next]
